FDG Cancer Imaging

Fluorodeoxyglucose (FDG) cancer imaging has revolutionized the way medical professionals diagnose and monitor cancer.

This imaging technique utilizes positron emission tomography (PET) scans to detect the increased metabolic activity characteristic of cancer cells. FDG, a radioactive glucose analog, is injected into the patient and accumulates in areas with elevated glucose metabolism, such as tumors.

The principle behind FDG cancer imaging lies in the fact that cancer cells often exhibit higher metabolic rates than normal cells. As a result, they absorb more FDG, leading to concentrated areas of radioactivity on PET scans. This allows healthcare providers to pinpoint the location and extent of tumors with remarkable precision.

FDG cancer imaging is particularly valuable for cancer staging, treatment planning, and monitoring treatment response. It enables physicians to identify primary tumors, detect metastases, and assess the overall metabolic activity of cancerous tissues. Moreover, the technique can differentiate between malignant and benign lesions, aiding in the development of personalized treatment strategies.